{
    "2019-09-05": [
        [
            {
                "time": "2018-01-02",
                "original_text": "ROSEN, A TOP RANKED LAW FIRM, Continues To Investigate Securities Claims Against Novartis AG â€“ NVS",
                "features": {
                    "keywords": [
                        "Rosen",
                        "securities claims",
                        "investigation",
                        "Novartis"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "Tagrisso",
                        "approval",
                        "China",
                        "NSCLC"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Novartis signs $840M pact with IFM Due amid fallout from AveXis deal",
                "features": {
                    "keywords": [
                        "Novartis",
                        "IFM",
                        "pact",
                        "AveXis",
                        "deal"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}